Cargando…
Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy
The addition of temozolomide (TMZ) to radiotherapy (RT) improves survival of patients with glioblastoma (GBM). However, TMZ + RT causes excess toxicity in patients. In this study, we prepared angiopep-2 (A2) modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles for TMZ delivery (A2...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394306/ https://www.ncbi.nlm.nih.gov/pubmed/30744436 http://dx.doi.org/10.1080/10717544.2018.1534897 |
_version_ | 1783398868709277696 |
---|---|
author | Zong, Zhenkun Hua, Lei Wang, Zhen Xu, Haoyue Ye, Chengkun Pan, Bomin Zhao, Zongren Zhang, Longzhen Lu, Jun Liu, Hongmei Yu, Rutong |
author_facet | Zong, Zhenkun Hua, Lei Wang, Zhen Xu, Haoyue Ye, Chengkun Pan, Bomin Zhao, Zongren Zhang, Longzhen Lu, Jun Liu, Hongmei Yu, Rutong |
author_sort | Zong, Zhenkun |
collection | PubMed |
description | The addition of temozolomide (TMZ) to radiotherapy (RT) improves survival of patients with glioblastoma (GBM). However, TMZ + RT causes excess toxicity in patients. In this study, we prepared angiopep-2 (A2) modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles for TMZ delivery (A2-P(MIs)25/TMZ) to achieve synergistic effects against glioma. This A2-P(MIs)25/TMZ display highly promising advantages: (1) a hydrophobic P-(MIs)25 core where poorly water-soluble TMZ can be encapsulated; (2) nitro groups of the hydrophobic P-(MIs)25 core that are converted into hydrophilic amino groups (P(NH(2)s)25) under low oxygen conditions to mimic the oxygen-increased sensitization to RT; (3) a lipid monolayer at the interface of the core and the shell to modify the A2 (a specific ligand for low-density lipoprotein receptor-related protein-1 (LRP-1), which are expressed in the blood-brain barrier (BBB) and human glioma cells), thereby enhancing the drug encapsulation efficiency in glioma. These nanoparticles appear as a promising and robust nanoplatforms for TMZ and hypoxic cell radiosensitization delivery. |
format | Online Article Text |
id | pubmed-6394306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-63943062019-03-04 Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy Zong, Zhenkun Hua, Lei Wang, Zhen Xu, Haoyue Ye, Chengkun Pan, Bomin Zhao, Zongren Zhang, Longzhen Lu, Jun Liu, Hongmei Yu, Rutong Drug Deliv Research Article The addition of temozolomide (TMZ) to radiotherapy (RT) improves survival of patients with glioblastoma (GBM). However, TMZ + RT causes excess toxicity in patients. In this study, we prepared angiopep-2 (A2) modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles for TMZ delivery (A2-P(MIs)25/TMZ) to achieve synergistic effects against glioma. This A2-P(MIs)25/TMZ display highly promising advantages: (1) a hydrophobic P-(MIs)25 core where poorly water-soluble TMZ can be encapsulated; (2) nitro groups of the hydrophobic P-(MIs)25 core that are converted into hydrophilic amino groups (P(NH(2)s)25) under low oxygen conditions to mimic the oxygen-increased sensitization to RT; (3) a lipid monolayer at the interface of the core and the shell to modify the A2 (a specific ligand for low-density lipoprotein receptor-related protein-1 (LRP-1), which are expressed in the blood-brain barrier (BBB) and human glioma cells), thereby enhancing the drug encapsulation efficiency in glioma. These nanoparticles appear as a promising and robust nanoplatforms for TMZ and hypoxic cell radiosensitization delivery. Taylor & Francis 2019-02-11 /pmc/articles/PMC6394306/ /pubmed/30744436 http://dx.doi.org/10.1080/10717544.2018.1534897 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zong, Zhenkun Hua, Lei Wang, Zhen Xu, Haoyue Ye, Chengkun Pan, Bomin Zhao, Zongren Zhang, Longzhen Lu, Jun Liu, Hongmei Yu, Rutong Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy |
title | Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy |
title_full | Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy |
title_fullStr | Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy |
title_full_unstemmed | Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy |
title_short | Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy |
title_sort | self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery tmz for glioma synergistic tmz and rt therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394306/ https://www.ncbi.nlm.nih.gov/pubmed/30744436 http://dx.doi.org/10.1080/10717544.2018.1534897 |
work_keys_str_mv | AT zongzhenkun selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy AT hualei selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy AT wangzhen selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy AT xuhaoyue selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy AT yechengkun selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy AT panbomin selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy AT zhaozongren selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy AT zhanglongzhen selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy AT lujun selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy AT liuhongmei selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy AT yurutong selfassembledangiopep2modifiedlipidpolyhypoxicradiosensitizedpolyprodrugnanoparticlesdeliverytmzforgliomasynergistictmzandrttherapy |